Cell Isolation Market / Cell Separation Market Size, Share & Trends by Product (Consumables [Media, Kits] Instruments), Cell Type (Human, Animal), Cell Source (Bone Marrow, Adipose Tissue), Technique (Centrifugation, Filtration), Application (Biomolecule, Cancer) - Global Forecast to 2029
The cell isolation market is expected to grow to USD 8.4 billion by 2029, up from USD 4.6 billion in 2024, at a CAGR of 12.9% between 2024 and 2029. Several significant factors contribute to the cell isolation market's potential growth. Government support for cell-based research is increasing, as is the prevalence of cancer and infectious disorders. Furthermore, there is a growing focus on technological developments and personalized medicine. Furthermore, emerging countries provide significant development opportunities, and the increased emphasis on next-generation treatments is expected to drive the market further.
“The biomedical isolation segment accounted for the largest share of by application segment in 2023.”
In 2023, the biomedical isolation segment held the largest share of the global cell isolation market by application. Cell isolation is an important process for isolating biomolecules as it allows researchers to focus on specific cell populations and extract target molecules for further analysis, characterization, and use in therapeutic or research applications. Major factors driving the growth of the cell isolation market for biomolecule isolation are the increasing demand for biopharmaceutical products for the treatment of infectious and chronic diseases, innovative and advanced applications of cell analysis techniques in biomolecule isolation, and the growth of the global biopharmaceutical industry.
“In 2023, the US remained to dominate the cell isolation market.”
The US dominated the North American cell isolation market in 2023. The US is the world's largest biopharmaceutical market and the leader in biopharmaceutical research and investment. The United States also has a strong healthcare infrastructure, which encourages research and development in the life sciences. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, growing focus on development of cell-based research due to growing prevalence of cancer is also driving the growth of the cell isolation market.
The primary interviews conducted for this report can be categorized as follows:
This research report categorizes the cell isolation market by product (consumables (reagents, kits, media & sera, beads (magnetic beads and fluroscent beads), and disposables) and instruments(centrifuges, cell sorters, magnetic-activated cell seperator systems, and filtration systems)), cell type (human cells (differentiated cells and stem cells) and animal cells), cell source (adipose tissues, bone marrow, cord blood/ embryonic stem cells, and others), technique (centrifugation-based cell isolation, surface-based cell isolation, and filtration-based cell isolation), application (biomolecule isolation, cancer research, stem cell research, tissue regeneration & regenerative medicine, in-vitro diagnostics, and others), end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic laboratories, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell isolation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the cell isolation market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell isolation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“The biomedical isolation segment accounted for the largest share of by application segment in 2023.”
In 2023, the biomedical isolation segment held the largest share of the global cell isolation market by application. Cell isolation is an important process for isolating biomolecules as it allows researchers to focus on specific cell populations and extract target molecules for further analysis, characterization, and use in therapeutic or research applications. Major factors driving the growth of the cell isolation market for biomolecule isolation are the increasing demand for biopharmaceutical products for the treatment of infectious and chronic diseases, innovative and advanced applications of cell analysis techniques in biomolecule isolation, and the growth of the global biopharmaceutical industry.
“In 2023, the US remained to dominate the cell isolation market.”
The US dominated the North American cell isolation market in 2023. The US is the world's largest biopharmaceutical market and the leader in biopharmaceutical research and investment. The United States also has a strong healthcare infrastructure, which encourages research and development in the life sciences. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, growing focus on development of cell-based research due to growing prevalence of cancer is also driving the growth of the cell isolation market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Thermo Fisher Scientific Inc. (US)
- BD (US)
- Agilent Technologies, Inc. (US)
- Miltenyi Biotec (Germany)
- Revvity (US)
- Sartorius AG (Germany)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Lonza (Switzerland)
- QIAGEN (Netherlands)
- ALFA LAVAL (Sweden)
- Terumo Corporation (Japan)
- Corning Incorporated (US)
- Bio-Rad Laboratories, Inc. (US)
- GenScript (US)
- Bio-Techne (US)
- Takara Bio Inc. (Japan)
- Standard BioTools (US)
- Promega Corporation (US)
- Cell Signaling Technology, Inc. (US)
- STEMCELL Technologies (Canada)
This research report categorizes the cell isolation market by product (consumables (reagents, kits, media & sera, beads (magnetic beads and fluroscent beads), and disposables) and instruments(centrifuges, cell sorters, magnetic-activated cell seperator systems, and filtration systems)), cell type (human cells (differentiated cells and stem cells) and animal cells), cell source (adipose tissues, bone marrow, cord blood/ embryonic stem cells, and others), technique (centrifugation-based cell isolation, surface-based cell isolation, and filtration-based cell isolation), application (biomolecule isolation, cancer research, stem cell research, tissue regeneration & regenerative medicine, in-vitro diagnostics, and others), end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic laboratories, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell isolation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the cell isolation market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell isolation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (surge in cases of cancer and infectious diseases and growing emphasis on technological advancements), restraints (ethical & safety issues and high cost of cell-based research), opportunities (growing focus on next generation sequencing), and Challenges (technical complexities and standardization issues) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the cell isolation market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell isolation market
- Competitive Assessment: . Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), BD (US), Agilent Technologies, Inc. (US), Miltenyi Biotec (Germany), Revvity (US), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Lonza (Switzerland), QIAGEN (Netherlands), ALFA LAVAL (Sweden), Terumo Corporation (Japan), Corning Incorporated (US), Bio-Rad Laboratories, Inc. (US), GenScript (US), Bio-Techne (US), Takara Bio Inc. (Japan), Standard BioTools (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), and STEMCELL Technologies (Canada), among others in the market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.4.1 Value unit
1.3.4.2 Volume unit
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CELL ISOLATION MARKET OVERVIEW
4.2 NORTH AMERICAN CELL ISOLATION MARKET, BY TYPE AND COUNTRY
4.3 CELL ISOLATION MARKET SHARE, BY APPLICATION
4.4 CELL ISOLATION MARKET SHARE, BY END USER
4.5 CELL ISOLATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing government funding for cell-based research
5.2.1.2 Surge in cases of cancer and infectious diseases
5.2.1.3 Rising emphasis on technological advancements and product developments
5.2.1.4 Growing focus on personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 Ethical and safety issues
5.2.2.2 High cost of cell-based research
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Increasing focus on next-generation therapeutics
5.2.4 CHALLENGES
5.2.4.1 Complex development process of cell therapies
5.2.4.2 Technical complexities and stringent regulatory requirements
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Centrifugation-based techniques
5.4.1.2 Magnetic cell isolation
5.4.1.3 Fluorescence-activated cell sorting
5.4.1.4 Acoustic cell isolation
5.4.1.5 Acoustofluidic cell isolation
5.4.1.6 Microfiltration
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Mass cytometry
5.4.2.2 Cell imaging technologies
5.4.2.3 Artificial intelligence and machine learning
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Single-cell sequencing
5.4.3.2 Clustered regularly interspaced short palindromic repeats
and gene editing
5.4.3.3 3D cell culture
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY TECHNIQUE
5.5.3 AVERAGE SELLING PRICE TREND, BY REGION
5.6 VALUE CHAIN ANALYSIS
5.7 PATENT ANALYSIS
5.8 SUPPLY CHAIN ANALYSIS
5.9 ECOSYSTEM ANALYSIS
5.9.1 ROLE OF RAW MATERIAL VENDORS
5.9.2 ROLE OF PRODUCT PROVIDERS
5.9.3 ROLE OF END USERS
5.9.4 ROLE OF REGULATORY AUTHORITIES
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.2 REGULATORY SCENARIO
5.11 PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY CONFERENCES AND EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.13.2 BUYING CRITERIA
5.14 TRADE ANALYSIS
5.14.1 IMPORT DATA FOR HS CODE 382200
5.14.2 EXPORT DATA FOR HS CODE 382200
5.15 INVESTMENT AND FUNDING SCENARIO
5.16 IMPACT OF GENERATIVE AI ON CELL ISOLATION MARKET
6 CELL ISOLATION MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS, KITS, MEDIA, AND SERA
6.2.1.1 Surge in product launches and repetitive purchases to boost segment growth
6.2.2 BEADS
6.2.2.1 Magnetic beads
6.2.2.1.1 Growing demand in biomedical research and clinical applications to drive market
6.2.2.2 Fluorescent beads
6.2.2.2.1 Increasing use in flow cytometry, cell sorting, and imaging applications to fuel market
6.2.3 DISPOSABLES
6.2.3.1 Growing government investments in research to aid market growth
6.3 INSTRUMENTS
6.3.1 CENTRIFUGES
6.3.1.1 Growing use in pharma-biotech industry to boost market
6.3.2 CELL SORTERS
6.3.2.1 Rise in cell-based research initiatives to augment growth
6.3.3 MAGNETIC-ACTIVATED CELL SEPARATOR SYSTEMS
6.3.3.1 Booming use in research for T-cell and stem cell isolation to drive market
6.3.4 FILTRATION SYSTEMS
6.3.4.1 Rising need to ensure Good Manufacturing Practice standards and regulations to boost market
7 CELL ISOLATION MARKET, BY CELL TYPE
7.1 INTRODUCTION
7.2 HUMAN CELLS
7.2.1 DIFFERENTIATED CELLS
7.2.1.1 Increasing use in disease modeling, regenerative medicine, and gene therapy to fuel growth
7.2.2 STEM CELLS
7.2.2.1 Rise in grants and funding for stem cell research to drive market
7.3 ANIMAL CELLS
7.3.1 GROWING INVESTMENTS FOR VACCINE AND DRUG DEVELOPMENT TO SUPPORT GROWTH
8 CELL ISOLATION MARKET, BY CELL SOURCE
8.1 INTRODUCTION
8.2 ADIPOSE TISSUE
8.2.1 INCREASING APPLICATIONS IN CLINICAL STUDIES AND TRIALS TO DRIVE MARKET
8.3 BONE MARROW
8.3.1 GROWING DEMAND FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS TO AID GROWTH
8.4 CORD BLOOD/EMBRYONIC STEM CELLS
8.4.1 HIGH THERAPEUTIC POTENCY TO SUPPORT MARKET GROWTH
8.5 OTHER CELL SOURCES
9 CELL ISOLATION MARKET, BY TECHNIQUE
9.1 INTRODUCTION
9.2 CENTRIFUGATION-BASED CELL ISOLATION
9.2.1 RISE IN USE BY BIOTECH AND BIOPHARMACEUTICAL COMPANIES TO FUEL MARKET
9.3 SURFACE MARKER-BASED CELL ISOLATION
9.3.1 INCREASING ADOPTION OF MAGNETIC-ACTIVATED CELL SORTING TO PROPEL MARKET
9.4 FILTRATION-BASED CELL ISOLATION
9.4.1 NEED FOR AFFORDABLE FILTRATION TECHNIQUE TO DRIVE MARKET
10 CELL ISOLATION MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 BIOMOLECULE ISOLATION
10.2.1 INCREASING DEMAND FOR BIOPHARMACEUTICAL PRODUCTS TO FUEL MARKET
10.3 CANCER RESEARCH
10.3.1 GROWING INCLINATION TOWARD DEVELOPING AND MANUFACTURING CANCER TREATMENTS TO DRIVE MARKET
10.4 STEM CELL RESEARCH
10.4.1 RISING GRANTS AND FUNDING FOR STEM CELL RESEARCH TO AUGMENT GROWTH
10.5 TISSUE REGENERATION & REGENERATIVE MEDICINE
10.5.1 GROWING INITIATIVES FOR RESEARCH IN REGENERATIVE MEDICINE TO SUPPORT MARKET
10.6 IN VITRO DIAGNOSTICS
10.6.1 NEED FOR ACCURACY TO IDENTIFY CELL TYPE TO PROPEL MARKET
10.7 OTHER APPLICATIONS
11 CELL ISOLATION MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 INCREASING INVESTMENTS BY KEY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO BOOST MARKET GROWTH
11.3 ACADEMIC & RESEARCH INSTITUTES
11.3.1 HIGH GOVERNMENT FUNDING FOR EDUCATIONAL PURPOSES TO FUEL SEGMENT
11.4 HOSPITALS & DIAGNOSTIC LABORATORIES
11.4.1 INCREASING NUMBER OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES TO DRIVE MARKET
11.5 OTHER END USERS
12 CELL ISOLATION MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 NORTH AMERICA: RECESSION IMPACT
12.2.2 US
12.2.2.1 Rising prevalence of cancer to drive market
12.2.3 CANADA
12.2.3.1 Increased government funding for stem cell and vaccine research to propel market
12.3 EUROPE
12.3.1 EUROPE: RECESSION IMPACT
12.3.2 GERMANY
12.3.2.1 Rising interest in biotechnology drugs and applications to aid market growth
12.3.3 UK
12.3.3.1 Increasing prevalence of infectious diseases to drive market
12.3.4 FRANCE
12.3.4.1 Surge in investments in cell biology research activities to drive market
12.3.5 ITALY
12.3.5.1 Rising number of cell biology seminars and conferences to drive market
12.3.6 SPAIN
12.3.6.1 Increasing funding from private and public organizations to aid growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 ASIA PACIFIC: RECESSION IMPACT
12.4.2 CHINA
12.4.2.1 Increasing investments in research and technological advancements to boost market
12.4.3 JAPAN
12.4.3.1 Dominant geriatric population to aid market growth
12.4.4 INDIA
12.4.4.1 Growing penetration of healthcare insurance services to propel market
12.4.5 AUSTRALIA
12.4.5.1 Growing emphasis on personalized medicine, biopharmaceuticals, and advanced therapies to fuel market
12.4.6 SOUTH KOREA
12.4.6.1 Rising need for therapeutics to support market growth
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 LATIN AMERICA: RECESSION IMPACT
12.5.2 BRAZIL
12.5.2.1 Need to improve public access to modern healthcare facilities to drive market
12.5.3 MEXICO
12.5.3.1 Favorable trade agreements to support market
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MIDDLE EAST: RECESSION IMPACT
12.6.2 GCC
12.6.2.1 Saudi Arabia
12.6.2.1.1 Growing focus on Vision 2030 initiatives to boost market
12.6.2.2 UAE
12.6.2.2.1 Rising inclination toward producing high-value specialty drugs to aid market growth
12.6.2.3 Rest of GCC Countries
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 INCREASING PATIENT POPULATION WITH CANCER TO PROPEL MARKET
12.7.2 AFRICA: RECESSION IMPACT
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL ISOLATION MARKET
13.3 REVENUE ANALYSIS, 2021–2023
13.4 MARKET SHARE ANALYSIS, 2023
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Type footprint
13.5.5.4 Cell type footprint
13.5.5.5 End user footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.8 BRAND/PRODUCT COMPARISON
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES
13.9.2 DEALS
13.9.3 EXPANSIONS
13.9.4 OTHER DEVELOPMENTS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 DANAHER CORPORATION
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Deals
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 MERCK KGAA
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.3.2 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 THERMO FISHER SCIENTIFIC INC.
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 BD
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches
14.1.4.3.2 Deals
14.1.4.3.3 Other developments
14.1.5 SARTORIUS AG
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Deals
14.1.6 AGILENT TECHNOLOGIES, INC.
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.7 BIO-RAD LABORATORIES, INC.
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches
14.1.8 QIAGEN
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.9 F. HOFFMANN-LA ROCHE LTD.
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.10 REVVITY
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Other developments
14.1.11 CORNING INCORPORATED
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.12 LONZA
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.12.3 Recent developments
14.1.12.3.1 Product launches
14.1.12.3.2 Deals
14.1.13 BIO-TECHNE
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Deals
14.1.13.3.2 Other developments
14.1.14 TERUMO CORPORATION
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Deals
14.1.15 MILTENYI BIOTEC
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.16 TAKARA BIO INC.
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Deals
14.1.17 GENSCRIPT
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.17.3 Recent developments
14.1.17.3.1 Deals
14.1.18 STANDARD BIOTOOLS
14.1.18.1 Business overview
14.1.18.2 Products offered
14.1.19 ALFA LAVAL
14.1.19.1 Business overview
14.1.19.2 Products offered
14.1.19.3 Recent developments
14.1.19.3.1 Product launches
14.1.19.3.2 Deals
14.2 OTHER PLAYERS
14.2.1 PROMEGA CORPORATION
14.2.2 CELL SIGNALING TECHNOLOGY, INC.
14.2.3 MICAREO INC.
14.2.4 APPLIED CELLS INC.
14.2.5 STEMCELL TECHNOLOGIES
14.2.6 CREATIVE BIOARRAY
14.2.7 PROTEINTECH GROUP, INC.
14.2.8 MAGBIO GENOMICS, INC.
14.2.9 AKADEUM LIFE SCIENCES
14.2.10 PLURISELECT LIFE SCIENCE UG (HAFTUNGSBESCHRДNKT) & CO. KG
14.2.11 INVENT BIOTECHNOLOGIES, INC.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.4.1 Value unit
1.3.4.2 Volume unit
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CELL ISOLATION MARKET OVERVIEW
4.2 NORTH AMERICAN CELL ISOLATION MARKET, BY TYPE AND COUNTRY
4.3 CELL ISOLATION MARKET SHARE, BY APPLICATION
4.4 CELL ISOLATION MARKET SHARE, BY END USER
4.5 CELL ISOLATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing government funding for cell-based research
5.2.1.2 Surge in cases of cancer and infectious diseases
5.2.1.3 Rising emphasis on technological advancements and product developments
5.2.1.4 Growing focus on personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 Ethical and safety issues
5.2.2.2 High cost of cell-based research
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Increasing focus on next-generation therapeutics
5.2.4 CHALLENGES
5.2.4.1 Complex development process of cell therapies
5.2.4.2 Technical complexities and stringent regulatory requirements
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Centrifugation-based techniques
5.4.1.2 Magnetic cell isolation
5.4.1.3 Fluorescence-activated cell sorting
5.4.1.4 Acoustic cell isolation
5.4.1.5 Acoustofluidic cell isolation
5.4.1.6 Microfiltration
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Mass cytometry
5.4.2.2 Cell imaging technologies
5.4.2.3 Artificial intelligence and machine learning
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Single-cell sequencing
5.4.3.2 Clustered regularly interspaced short palindromic repeats
and gene editing
5.4.3.3 3D cell culture
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY TECHNIQUE
5.5.3 AVERAGE SELLING PRICE TREND, BY REGION
5.6 VALUE CHAIN ANALYSIS
5.7 PATENT ANALYSIS
5.8 SUPPLY CHAIN ANALYSIS
5.9 ECOSYSTEM ANALYSIS
5.9.1 ROLE OF RAW MATERIAL VENDORS
5.9.2 ROLE OF PRODUCT PROVIDERS
5.9.3 ROLE OF END USERS
5.9.4 ROLE OF REGULATORY AUTHORITIES
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.2 REGULATORY SCENARIO
5.11 PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY CONFERENCES AND EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.13.2 BUYING CRITERIA
5.14 TRADE ANALYSIS
5.14.1 IMPORT DATA FOR HS CODE 382200
5.14.2 EXPORT DATA FOR HS CODE 382200
5.15 INVESTMENT AND FUNDING SCENARIO
5.16 IMPACT OF GENERATIVE AI ON CELL ISOLATION MARKET
6 CELL ISOLATION MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS, KITS, MEDIA, AND SERA
6.2.1.1 Surge in product launches and repetitive purchases to boost segment growth
6.2.2 BEADS
6.2.2.1 Magnetic beads
6.2.2.1.1 Growing demand in biomedical research and clinical applications to drive market
6.2.2.2 Fluorescent beads
6.2.2.2.1 Increasing use in flow cytometry, cell sorting, and imaging applications to fuel market
6.2.3 DISPOSABLES
6.2.3.1 Growing government investments in research to aid market growth
6.3 INSTRUMENTS
6.3.1 CENTRIFUGES
6.3.1.1 Growing use in pharma-biotech industry to boost market
6.3.2 CELL SORTERS
6.3.2.1 Rise in cell-based research initiatives to augment growth
6.3.3 MAGNETIC-ACTIVATED CELL SEPARATOR SYSTEMS
6.3.3.1 Booming use in research for T-cell and stem cell isolation to drive market
6.3.4 FILTRATION SYSTEMS
6.3.4.1 Rising need to ensure Good Manufacturing Practice standards and regulations to boost market
7 CELL ISOLATION MARKET, BY CELL TYPE
7.1 INTRODUCTION
7.2 HUMAN CELLS
7.2.1 DIFFERENTIATED CELLS
7.2.1.1 Increasing use in disease modeling, regenerative medicine, and gene therapy to fuel growth
7.2.2 STEM CELLS
7.2.2.1 Rise in grants and funding for stem cell research to drive market
7.3 ANIMAL CELLS
7.3.1 GROWING INVESTMENTS FOR VACCINE AND DRUG DEVELOPMENT TO SUPPORT GROWTH
8 CELL ISOLATION MARKET, BY CELL SOURCE
8.1 INTRODUCTION
8.2 ADIPOSE TISSUE
8.2.1 INCREASING APPLICATIONS IN CLINICAL STUDIES AND TRIALS TO DRIVE MARKET
8.3 BONE MARROW
8.3.1 GROWING DEMAND FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS TO AID GROWTH
8.4 CORD BLOOD/EMBRYONIC STEM CELLS
8.4.1 HIGH THERAPEUTIC POTENCY TO SUPPORT MARKET GROWTH
8.5 OTHER CELL SOURCES
9 CELL ISOLATION MARKET, BY TECHNIQUE
9.1 INTRODUCTION
9.2 CENTRIFUGATION-BASED CELL ISOLATION
9.2.1 RISE IN USE BY BIOTECH AND BIOPHARMACEUTICAL COMPANIES TO FUEL MARKET
9.3 SURFACE MARKER-BASED CELL ISOLATION
9.3.1 INCREASING ADOPTION OF MAGNETIC-ACTIVATED CELL SORTING TO PROPEL MARKET
9.4 FILTRATION-BASED CELL ISOLATION
9.4.1 NEED FOR AFFORDABLE FILTRATION TECHNIQUE TO DRIVE MARKET
10 CELL ISOLATION MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 BIOMOLECULE ISOLATION
10.2.1 INCREASING DEMAND FOR BIOPHARMACEUTICAL PRODUCTS TO FUEL MARKET
10.3 CANCER RESEARCH
10.3.1 GROWING INCLINATION TOWARD DEVELOPING AND MANUFACTURING CANCER TREATMENTS TO DRIVE MARKET
10.4 STEM CELL RESEARCH
10.4.1 RISING GRANTS AND FUNDING FOR STEM CELL RESEARCH TO AUGMENT GROWTH
10.5 TISSUE REGENERATION & REGENERATIVE MEDICINE
10.5.1 GROWING INITIATIVES FOR RESEARCH IN REGENERATIVE MEDICINE TO SUPPORT MARKET
10.6 IN VITRO DIAGNOSTICS
10.6.1 NEED FOR ACCURACY TO IDENTIFY CELL TYPE TO PROPEL MARKET
10.7 OTHER APPLICATIONS
11 CELL ISOLATION MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 INCREASING INVESTMENTS BY KEY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO BOOST MARKET GROWTH
11.3 ACADEMIC & RESEARCH INSTITUTES
11.3.1 HIGH GOVERNMENT FUNDING FOR EDUCATIONAL PURPOSES TO FUEL SEGMENT
11.4 HOSPITALS & DIAGNOSTIC LABORATORIES
11.4.1 INCREASING NUMBER OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES TO DRIVE MARKET
11.5 OTHER END USERS
12 CELL ISOLATION MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 NORTH AMERICA: RECESSION IMPACT
12.2.2 US
12.2.2.1 Rising prevalence of cancer to drive market
12.2.3 CANADA
12.2.3.1 Increased government funding for stem cell and vaccine research to propel market
12.3 EUROPE
12.3.1 EUROPE: RECESSION IMPACT
12.3.2 GERMANY
12.3.2.1 Rising interest in biotechnology drugs and applications to aid market growth
12.3.3 UK
12.3.3.1 Increasing prevalence of infectious diseases to drive market
12.3.4 FRANCE
12.3.4.1 Surge in investments in cell biology research activities to drive market
12.3.5 ITALY
12.3.5.1 Rising number of cell biology seminars and conferences to drive market
12.3.6 SPAIN
12.3.6.1 Increasing funding from private and public organizations to aid growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 ASIA PACIFIC: RECESSION IMPACT
12.4.2 CHINA
12.4.2.1 Increasing investments in research and technological advancements to boost market
12.4.3 JAPAN
12.4.3.1 Dominant geriatric population to aid market growth
12.4.4 INDIA
12.4.4.1 Growing penetration of healthcare insurance services to propel market
12.4.5 AUSTRALIA
12.4.5.1 Growing emphasis on personalized medicine, biopharmaceuticals, and advanced therapies to fuel market
12.4.6 SOUTH KOREA
12.4.6.1 Rising need for therapeutics to support market growth
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 LATIN AMERICA: RECESSION IMPACT
12.5.2 BRAZIL
12.5.2.1 Need to improve public access to modern healthcare facilities to drive market
12.5.3 MEXICO
12.5.3.1 Favorable trade agreements to support market
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MIDDLE EAST: RECESSION IMPACT
12.6.2 GCC
12.6.2.1 Saudi Arabia
12.6.2.1.1 Growing focus on Vision 2030 initiatives to boost market
12.6.2.2 UAE
12.6.2.2.1 Rising inclination toward producing high-value specialty drugs to aid market growth
12.6.2.3 Rest of GCC Countries
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 INCREASING PATIENT POPULATION WITH CANCER TO PROPEL MARKET
12.7.2 AFRICA: RECESSION IMPACT
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL ISOLATION MARKET
13.3 REVENUE ANALYSIS, 2021–2023
13.4 MARKET SHARE ANALYSIS, 2023
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Type footprint
13.5.5.4 Cell type footprint
13.5.5.5 End user footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.8 BRAND/PRODUCT COMPARISON
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES
13.9.2 DEALS
13.9.3 EXPANSIONS
13.9.4 OTHER DEVELOPMENTS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 DANAHER CORPORATION
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Deals
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 MERCK KGAA
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.3.2 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 THERMO FISHER SCIENTIFIC INC.
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 BD
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches
14.1.4.3.2 Deals
14.1.4.3.3 Other developments
14.1.5 SARTORIUS AG
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Deals
14.1.6 AGILENT TECHNOLOGIES, INC.
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.7 BIO-RAD LABORATORIES, INC.
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches
14.1.8 QIAGEN
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.9 F. HOFFMANN-LA ROCHE LTD.
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.10 REVVITY
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Other developments
14.1.11 CORNING INCORPORATED
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.12 LONZA
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.12.3 Recent developments
14.1.12.3.1 Product launches
14.1.12.3.2 Deals
14.1.13 BIO-TECHNE
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Deals
14.1.13.3.2 Other developments
14.1.14 TERUMO CORPORATION
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Deals
14.1.15 MILTENYI BIOTEC
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.16 TAKARA BIO INC.
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Deals
14.1.17 GENSCRIPT
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.17.3 Recent developments
14.1.17.3.1 Deals
14.1.18 STANDARD BIOTOOLS
14.1.18.1 Business overview
14.1.18.2 Products offered
14.1.19 ALFA LAVAL
14.1.19.1 Business overview
14.1.19.2 Products offered
14.1.19.3 Recent developments
14.1.19.3.1 Product launches
14.1.19.3.2 Deals
14.2 OTHER PLAYERS
14.2.1 PROMEGA CORPORATION
14.2.2 CELL SIGNALING TECHNOLOGY, INC.
14.2.3 MICAREO INC.
14.2.4 APPLIED CELLS INC.
14.2.5 STEMCELL TECHNOLOGIES
14.2.6 CREATIVE BIOARRAY
14.2.7 PROTEINTECH GROUP, INC.
14.2.8 MAGBIO GENOMICS, INC.
14.2.9 AKADEUM LIFE SCIENCES
14.2.10 PLURISELECT LIFE SCIENCE UG (HAFTUNGSBESCHRДNKT) & CO. KG
14.2.11 INVENT BIOTECHNOLOGIES, INC.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
